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OBJECTIVES: To compare the direct medical costs asso-
ciated with two different regimens for the treatment of
Helicobacter pylori-related peptic ulcer disease (PUD)
from a hospital perspective. The efficacy of a new regimen,
including ranitidine bismuth citrate, amoxycillin and cla-
rithromycin (RAC), was recently compared in a study at a
local teaching hospital with that of a regimen consisting of
omeprazole, amoxycillin and clarithromycin (OAC). The
study results showed no significant difference in the effi-
cacy of the two regimens, but the cost implication of the
two regimens was not examined. The drug cost of OAC
(HK$364, $US  7.8HK) was 20% more than that of
RAC (HK$304) for a 7-day therapy.
METHOD: Data from a controlled, randomized clinical
trial conducted in Hong Kong was reanalyzed. The
records of 100 patients with Helicobacter pylori-related
PUD, who were previously randomized to receive either
RAC or OAC, were reviewed. The hospital resources con-
sumed during the period of PUD treatment were retrieved
and studied. The total cost associated with each regimen
per ulcer-healed patient was calculated and analyzed.
RESULTS: Twelve of the 100 patients were excluded from
the analysis because of incomplete documentation or non-
compliance with the protocol of the clinical trial. Forty-
one inpatients and 47 outpatients were included in the
analysis. In the inpatient group, there was no significant
difference between the median direct cost associated with
OAC and RAC ($13,042 and $11,622, respectively; P 
0.168). In the outpatient group, the median direct cost as-
sociated with RAC was significantly lower than that of
OAC ($4,096 and $3,839, respectively; P  0.003).
CONCLUSION: The direct medical costs associated with
OAC and RAC were similar for inpatient treatment of
Helicobacter pylori-related PUD but RAC was less costly
in the outpatient setting.
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INTRODUCTION: A randomised multi-centre phase III
trial using Filgrastim (5 g/kg/day until neutrophil recov-
ery) in induction and consolidation therapy for ‘de novo’
adult acute myeloid leukaemia (AML) patients showed
safety and efficacy of the drug with significant reduction in
hospital duration and IV anti-infective drug therapy (Heil
et al, Blood, 1997, 90, 4710–4718).
OBJECTIVE: Considering the Belgium patients enrolled
in the trial to estimate the financial impact of Filgrastim
use in the treatment of AML for that country.
METHODS: Retrospective data collection of resource use
was obtained from the 36 Belgian patients (20 cases and
16 controls) enrolled through 3 hospitals. The data were
retrieved from Case Report Forms and hospital bills. The
cost perspective considered is the reimbursement authority
of Belgium. A cost-minimisation model is developed in-
cluding the following resource items: hospital duration, IV
anti-infective drug days, lab test days, blood transfusion
units, vials of Filgrastim, other drug use excluding chemo-
therapy, and use of other diagnostic tests (Rx, Scans). Unit
costs in 1998 BEF are retrieved from the reimbursement
authority (RIZIV/INAMI), the Red Cross Blood Bank, the
database of the Belgium Pharmaceutical Association (APB),
and a private database on cost of health care in Belgium
hospitals (CECODI).
RESULTS: The cost model shows an average cost decrease
of 73.31 BEF (5,7%) per patient for induction and consol-
idation therapy with Filgrastim. Sensitivity analysis on
hospital day costs that may widely vary, shows a break-
even point reached at a cost per day much lower than the
minimum reimbursement cost (break-even point  952
BEF).
CONCLUSIONS: Filgrastim use in the treatment of AML
patients in Belgium is likely to induce cost savings. The
cost results are conservative estimates that do not include
indirect cost evaluations and quality of life improvement
of the patient due to earlier hospital discharge.
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OBJECTIVE: To evaluate the economic implications of
amlodipine therapy in patients with advanced left ventric-
ular dysfunction due to nonischemic dilated cardiomyopa-
thy by using data from the Prospective Randomized Amlo-
dipine Survival Evaluation (PRAISE).
METHODS: By using a decision analytic model, costs and
effects were estimated for the first 2 years of observation in
PRAISE and were projected for 30 years after initiation of
therapy (referred to as the lifetime projection).
RESULTS: While statistical tests of the survival curves
indicated that amlodipine significantly improved survival
(P  0.001), differences in life expectancy (amlodipine,
0.19 years (95% CI, 0.03 to 0.41 years during the first
2 years of the trial; 2.89 years, 95% CI, 0.37 to 6.14
years projected for the patient’s lifetime) were not signifi-
cant. The ratios of cost per year of life saved were
$8000; those of cost per quality-adjusted year of life
saved were $14,300. The confidence intervals for the
cost-effectiveness ratios indicated that for the first 2 years
of the trial, amlodipine was unlikely to have ratios
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$58,000 per year of life saved and $124,000 per quality-
adjusted year of life saved. For the lifetime projection, it
was unlikely to have ratios $28,000 per year of life saved
and $54,000 per quality-adjusted year of life saved.
CONCLUSIONS: Among patients whose heart failure
was due to nonischemic dilated cardiomyopathy, amlo-
dipine therapy was good value for the cost. An economic
evaluation should be repeated when the second PRAISE
study—which was designed to evaluate the mortality ef-
fects in heart failure of nonischemic etiology—is com-
pleted.
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OBJECTIVES: An international review of cost-effective-
ness studies of pharmaceuticals published in the last 5
years in peer reviewed journals was undertaken to identify
the extent to which “state of the art” methodology and ana-
lytical techniques had been employed.
METHODS: Three main approaches were taken for this
review: (1) A literature search for cost-effectiveness analy-
ses of pharmaceuticals 1994–99 was undertaken using
MEDLINE and other databases; (2) A list of “state of the
art” methods and analytical techniques (defined as new
and innovative, rather than established) were drawn from
“methods” papers published in leading health economics
journals in the past 10 years, and peer opinion; (3) Appli-
cation of a simple quality scoring system to assess the
quality of the reviewed papers.
RESULTS: 30 (currently) economic evaluations of phar-
maceuticals have to date been identified, originating from
several countries. The “state of the art” methods list in-
cluded developments in a several main areas: data collec-
tion and modelling approaches (e.g., RCTs, meta analysis
and scenario analysis), cost measurement, analysis and
handling uncertainty (e.g., confidence intervals for ICERs,
Monte Carlo simulations, Bayesian approaches to sensitiv-
ity analysis). The quality scoring system is still in develop-
ment (although pilot results hopefully due soon). The main
finding was that only a few of the studies reviewed used
“state of the art” methods, relying mostly on established
approaches to CEA.
CONCLUSIONS: The development of new state of the art
methods in CEA in recent years, in particular with new de-
velopments in statistical applications, has increased poten-
tial quality and rigour of CEA results. However, these
methods are not yet routinely used in actual pharmaceco-
nomic evaluations and may not be until more fully inte-
grated into the growing number of pharmacoeconomic
guidelines (linked to drug reimbursement) being produced
in different countries.
TPL2
MULTINATIONAL ECONOMIC EVALUATIONS: 
A REVIEW OF PUBLISHED STUDIES, 
METHODOLOGICAL ISSUES AND PRACTICE
Pang F
Centre for Health Economics, University of York, York, UK
OBJECTIVES: There is growing interest in the economic
evaluation of pharmaceuticals at the multinational level.
The purpose of these evaluations is to inform healthcare
decision-makers about the cost-effectiveness of pharma-
ceuticals, whose interests are largely specific to their own
countries. The objective of this research is to identify and
critically appraise multinational economic evaluations re-
lating to pharmaceuticals in a number of disease areas, to
produce a comprehensive list of the methodological con-
siderations and to demonstrate how previous work can in-
form and ensure optimal design and analysis of future
multinational economic evaluations.
METHODS: A systematic review involving databases (in-
cluding MEDLINE, OHE, NHS) and hand-searches of
journals was conducted for multinational economic evalu-
ations. Each economic evaluation was assessed using a 70-
point checklist specifically developed for multinational
economic evaluations, which evaluated design issues (study
question, study bias, outcomes) and analysis issues (data
pooling, data presentation, data robustness and data gen-
eralisability) and also scored against a previously devel-
oped 35 point generic checklist based on the BMJ guide-
lines. Simultaneously a review was performed on the
literature on generalisability and a survey was conducted
in a number of countries to ascertain attitudes to general-
isability of data from multinational clinical trials.
RESULTS: 16 economic evaluations met the criteria for in-
clusion, which were based on a variety of frameworks and
all took the form of cost-effectiveness analyses (5  multi-
national clinical-economic trials, 7  adaptation of single
country clinical-economic trials and 4  multinational de-
cision-analytic models) With the 70-point checklist, it was
found that the studies addressed different subsections of
the checklist adequately and the quality of the studies
showed further variation using the 35-point checklist.
There were very few papers on generalisability, but the re-
sults of the survey demonstrated a degree of convergence.
CONCLUSIONS: Worldwide, the issue of multinational
economic evaluations is generating huge interest and is one
of the biggest challenges facing health economics today.
However this area has not been extensively researched and
there is an urgent need for additional methodological
work. This research is a first step towards developing a set
of guidelines for use in future studies relating to the design,
analysis and presentation of multinational economic
evaluations with the purpose of maximizing the general-
isability of these studies and hence their value to decision-
makers.
